1. |
[J]. Surgeon, 2005; 3(3)∶210.
|
2. |
[J]. Ann Surg, 2001; 233(2)∶236.
|
3. |
[J]. ChineseGerman J Clin Oncol, 2004; 3(3)∶130.
|
4. |
[J]. J R Soc Med, 1985; 78(10)∶826.
|
5. |
[J]. Cancer, 1990; 66(1)∶135.
|
6. |
[J]. Eur J Cancer, 1990; 26(4)∶545.
|
7. |
[J]. Hepatology, 2000; 31(1)∶54.
|
8. |
[J]. J Cancer Res Clin Oncol, 2003; 129(1)∶17.
|
9. |
Lau WY. Primary hepatocellular carcinoma [A]. In: Blumgart LH, Fong Y Eds. Disease of the Liver and Biliary Tract [M]. 3rd edn. London: WB Saunders Co. Ltd, 2000∶1423.
|
10. |
Lau WY. Management of hepatocellular carcinoma [J]. J R Coll Surg Edinb, 2002; 47(1)∶389.
|
11. |
Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres [J]. Int J Radiat Oncol Biol Phys, 1998; 40(3)∶583.
|
12. |
Lai EC, Lau WY. The continuing challenge of hepatic cancer in Asia.
|
13. |
Lau WY, Yu SC, Lai EC, et al. Transarterial chemoembolization for hepatocellular carcinoma [J]. J Am Coll Surg, 2006; 202(1)∶155.
|
14. |
Lau WY, Leung TW, Yu SC, et al. Percutaneous local ablatire therapy for hepatocellular carcinoma: a review and lood into the future [J]. Ann Surg, 2003; 237(2)∶171.
|
15. |
Leung TW, Johnson PJ. Systemic therapy for hepatocellular carcinoma [J]. Semin Oncol, 2001; 28(5)∶514.
|
16. |
Lau WY, Leung TW, Lai BS, et al. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma.
|
17. |
Lau WY. Cure is possible with salvage surgery following downstaging of hepatocellular carcinoma.
|
18. |
Lai CL, Wu PC, Lok AS, et al. Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial [J]. Br J Cancer, 1989; 60(6)∶928.
|
19. |
Lai CL, Lau JY, Wu PC, et al. Recombinant interferonalpha in inoperable hepatocellular carcinoma: a randomized controlled trial [J]. Hepatology, 1993; 17(3)∶389.
|
20. |
Forbes A, Johnson PJ, Williams R. Recombinant human gammainterferon in primary hepatocellular carcinoma.
|
21. |
The Gastrointestinal Tumor Study Group. A prospective trial of recombinant human interferon alpha 2B in previously untreated patients with hepatocellular carcinoma.
|
22. |
Yoshida T, Okazaki N, Yoshino M, et al. Phase Ⅱ trial of high dose recombinant gammainterferon in advanced hepatocellular carcinoma.
|
23. |
Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma.
|
24. |
Kardinal CG, Moertel CG, Wieand HS, et al. Combined doxorubicin and alphainterferon therapy of advanced hepatocellular carcinoma [J]. Cancer, 1993; 71(7)∶2187.
|
25. |
Bokemeyer C, Kynast B, Harstrick A, et al.No synergistic activity of epirubicin and interferonalpha 2b in the treatment of hepatocellular carcinoma [J]. Cancer Chemother Pharmacol,1995; 35(4)∶334.
|
26. |
Patt YZ, Hassan MM, Lozano RD, et al. Phase Ⅱ trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa2b for treatment of hepatocellular carcinoma [J]. J Clin Oncol, 2003; 21(3)∶421.
|
27. |
Feun LG, O’Brien C, Molina E, et al. Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinomaA phase Ⅱ trial.
|
28. |
Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma [J]. Clin Cancer Res, 1999; 5(7)∶1676.
|
29. |
Leung TW, Tang AM, Zee B, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferonalpha, doxorubicin and 5fluorouracil chemotherapy [J]. Cancer, 2002; 94(2)∶421.
|
30. |
Yin XY, Lu MD, Liang LJ, et al. Systemic chemoimmunotherapy for advancedstage hepatocellular carcinoma [J]. World J Gastroenterol, 2005; 11(16)∶2526.
|
31. |
Yeo W, Mok TS, Zee B, et al. A randomized phase Ⅲ study of doxorubicin versus cisplatin/interferon alpha2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma [J]. J Natl Cancer Inst, 2005; 97(20)∶1532.
|
32. |
Lau WY, Ho SK, Yu SC, et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma [J]. Ann Surg, 2004; 240(2)∶299.
|